Hepatitis C Disease Forecast and Market Analysis to 2035: Focus on Pricing & Reimbursement, Marketed Drugs, Pipeline, Epidemiology, Treatment & Forecasts

Dublin, May 30, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Hepatitis C Disease Forecast and Market Analysis to 2035" report to their offering.

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridae virus family and is a communicable disease spread primarily through direct contact with the blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission. Hepatitis C infection normally does not produce signs or symptoms and, as such, most people who are infected do not know they have the disease. Approximately 15% of infected individuals are able to clear the virus and are free from associated complications.

The remaining 85% of individuals are at risk of chronic hepatitis and complications associated with chronic infection, such as scarring, liver cancer, and liver failure. An estimated 20-30% of chronic HCV patients go on to develop cirrhosis, while 1-5% will develop liver cancer.

Key Topics Covered:

1. FORECAST: HEPATITIS C
Executive Summary
Market Overview and Trends
Market Definition and Methodology
Daklinza (daclatasvir)
glecaprevir/pibrentasvir
Harvoni (sofosbuvir/ledipasvir)
Olysio (simeprevir)
sofosbuvir/velpatasvir
sofosbuvir/velpatasvir/GS-9857
Sovaldi (sofosbuvir)
Sunvepra (asunaprevir)
Technivie (paritaprevir/ritonavir/ombitasvir)
Viekira Pak (paritaprevir/ritonavir/ombitasvir + dasabuvir)
Zepatier (grazoprevir/elbasvir)
Primary Research Methodology

2. TREATMENT: HEPATITIS C
Executive Summary
Primary Research Methodology
Disease Definition and Diagnosis
Patient Segmentation
Current Treatment Options
Country Treatment Trees
Prescribing Trends
Unmet Needs in Hepatitis C

3. EPIDEMIOLOGY: HEPATITIS C IN THE US, JAPAN, AND 5EU
Executive Summary
Disease Overview
Sources and Methodology
Forecast
Epidemiologist Insight
Strengths and Limitations
Appendix

4. MARKETED DRUGS: HEPATITIS C
Executive Summary
Product Overview
Product profile: Daklinza
Product profile: Epclusa
Product profile: Harvoni
Product profile: Olysio
Product profile: Sovaldi
Product profile: Sunvepra
Product profile: Viekira Pak
Product profile: Zepatier

5. HEPATITIS C PRICING AND REIMBURSEMENT
Executive Summary
Market Context
US
Japan
Five Major EU Markets

6. PIPELINE: HEPATITIS C
Executive Summary
Clinical Pipeline Overview
Early-Phase Opportunities
Product profile (late stage): DCV-TRIO
Product profile (late stage): glecaprevir/pibrentasvir
Product profile (late stage): sofosbuvir/velpatasvir/voxilaprevir

For more information about this report visit http://www.researchandmarkets.com/research/tz9mdc/hepatitis_c


CONTACT: 


CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Infectious Diseases Drugs, Liver and Kidney Disorders Drugs 

Ads

You May Also Like

BeiGene to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical ...

Helix BioPharma Corp. Board Changes

RICHMOND HILL, Ontario, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) ...